Pronostic and Therapeutic Consequences of Gsα Mutations in Somatotroph Adenomas1

Pronostic and Therapeutic Consequences of Gsα Mutations in Somatotroph Adenomas1
复制标题

生长激素细胞腺瘤中 Gsα 突变的前额和治疗后果1

DOI:
--
复制
发表时间:
1998
期刊:
影响因子:
--
通讯作者:
P. Jaquet
P. Jaquet
中科院分区:
--
文献类型:
--
作者:
A. Barlier;G. Gunz;Alfredo J. Zamora;I. Morange;D. Figarella;Henri Dufour;A. Enjalbert;P. Jaquet

文献摘要

参考文献

被引文献

相似文献

人垂体生长激素细胞腺瘤可能与 G 蛋白 s α 亚基的突变有关。然而,目前gsp突变对肿瘤表型的影响尚不清楚。本研究旨在确定这种突变的检测是否会影响肢端肥大症患者的治疗。我们检查了 30 名肢端肥大症患者; 8 例为 gsp 阳性,22 例为 gsp 阴性。当考虑基础 GH 水平/肿瘤大小的比率时,gsp 阳性腺瘤似乎分泌更多。在体内(短期和长期)和体外条件下清楚地显示突变腺瘤具有更好的奥曲肽敏感性。在急性奥曲肽测试期间,gsp 阳性腺瘤中的 GH 最低值显着较低(最大抑制的 85% 与 52%)。 18 名患者在手术前接受了奥曲肽(300 微克/天)治疗至少 3 个月:gsp 阳性腺瘤中 GH 分泌过多的抑制百分比更高(76% 对比 47%)。在细胞培养中,奥曲肽诱导的 GH 释放抑制在 gsp 阳性腺瘤中显着较高(71% vs. 30%)。最后,在术后 2 年的随访期间,所有 gsp 突变患者的 GH 分泌过多均得到控制,即使是术后残留肿瘤组织的患者也是如此。相反,在 gsp 阴性组中,奥曲肽治疗无法控制 4 名携带肿瘤残留的患者的分泌过多。因此,Gs α突变可能成为预测肿瘤对生长抑素类似物控制的敏感性的新标记,从而改善预后。
Human pituitary somatotroph adenomas can be associated with mutations of the s alpha-subunit of G proteins. However, the impact of the gsp mutations on the tumoral phenotype is not well understood at present. This study aims to determine whether the detection of this mutation could impact on the management of acromegalic patients. We examined 30 acromegalic patients; 8 were gsp positive, and 22 were gsp negative. The gsp-positive adenomas appeared to secrete significantly more when the ratio of basal GH level/tumor size was considered. A better octreotide sensitivity of mutated adenomas was clearly shown under in vivo (short and long term) and in vitro conditions. During the acute octreotide test, the GH nadir was significantly lower in the gsp-positive adenomas (85% of maximal inhibition vs. 52%). Eighteen patients were treated with octreotide (300 micrograms/day) for at least 3 months before surgery: the percent inhibition of GH hypersecretion was higher in gsp-positive adenomas (76% vs. 47%). In cell culture, the octreotide-induced inhibition of GH release was significantly higher in gsp-positive adenomas (71% vs. 30%). Finally, during 2 yr of postoperative follow-up, GH hypersecretion was controlled in all patients with gsp mutation even in those in whom tumoral tissue remained after surgery. On the contrary, in the gsp-negative group, octreotide treatment was unable to control hypersecretion in 4 patients bearing tumoral remnants. The Gs alpha mutation could, therefore, be a new marker to foresee the susceptibility of the tumor to be controlled by somatostatin analogs, which improves prognosis.
环腺苷 3,5-单磷酸反应因子 CREB ​​在人生长激素细胞腺瘤中被组成型激活。
DOI: 10.1210/mend.9.7.7476961
发表时间: 1995
期刊: Molecular endocrinology (Baltimore, Md.)
影响因子: --
作者:
Bertherat,J;Chanson,P;Montminy,M
通讯作者: Montminy,M
DOI: 10.1210/mend.11.8.9957
发表时间: 1997-07
影响因子: --
作者:
X. Yang;F. Lee;G. Wand
通讯作者: X. Yang;F. Lee;G. Wand
具有和不具有 Gs α 突变的生长激素细胞腺瘤中糖蛋白激素 α 亚基的产生。
DOI: 10.1210/jcem.75.3.1517386
发表时间: 1992
期刊: The Journal of clinical endocrinology and metabolism
影响因子: --
作者:
Harris,PE;Alexander,JM;Bikkal,HA;Hsu,DW;Hedley-Whyte,ET;Klibanski,A;Jameson,JL
通讯作者: Jameson,JL
肢端肥大症体内和体外生长激素分泌对生长抑素敏感性的比较。
DOI: 10.1210/jcem-67-5-958
发表时间: 1988
期刊: The Journal of clinical endocrinology and metabolism
影响因子: --
作者:
Kelijman,M;Williams,TC;Downs,TR;Frohman,LA
通讯作者: Frohman,LA
组成型活性 G(S) α 亚基通过蛋白激酶 A 介导的途径刺激 Pit-1 启动子活性,该途径通过 Pit-1 和腺苷 3,5-单磷酸反应元件结合蛋白的脱氧核糖核酸结合位点发挥作用。
DOI: 10.1210/endo.137.4.8625901
发表时间: 1996
期刊: Endocrinology
影响因子: 4.8
作者:
Gaiddon,C;Tian,J;Loeffler,JP;Bancroft,C
通讯作者: Bancroft,C